SCHEMBL680086

SCHEMBL680086

Nc1ccc(Oc2cc3cnn(C4CCCCO4)c3cc2-c2ccc(NC(=O)O)nc2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
PIK3CD O00329 2/20 0.37
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
NR1H4 Q96RI1 1/20 0.33
AXL P30530 2/20 0.33
MERTK Q12866 2/20 0.33
PLK4 O00444 1/20 0.33
NTRK1 P04629 1/20 0.33
RET P07949 1/20 0.33
MET P08581 1/20 0.33
KDR P35968 1/20 0.33
FLT3 P36888 1/20 0.33
MST1R Q04912 1/20 0.33
DDR1 Q08345 1/20 0.33
CAMK4 Q16566 1/20 0.33
DDR2 Q16832 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679358 0.88 RXRA (0.41) RXRARXRBRXRGPIK3CDCYP4F2
SCHEMBL679359 0.88 RXRA (0.41) RXRARXRBRXRGPIK3CDCYP4F2
SCHEMBL680688 0.86 RXRB (0.44) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680860 0.83 RXRA (0.43) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680363 0.82 ATR (0.40) RXRARXRBRXRGSCN9A
SCHEMBL680337 0.82 RXRA (0.50) RXRARXRBRXRGPIK3CDCYP4F2
SCHEMBL680848 0.81 RXRA (0.53) RXRARXRBRXRGPIK3CDCYP4F2
SCHEMBL680965 0.77 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL679392 0.76 AXL (0.41) RXRARXRBRXRGAXLMERTK
SCHEMBL680051 0.73 RXRA (0.42) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.